WHAT WE DO

• Portfolio management and asset valuation
• Early development and innovation
• Integrated clinical development
• Approval and access
• Value substantiation lifecycle management

HOW WE DO IT

• Delivery models
• Operational excellence
• Medical affairs

Therapeutic Expertise

• Neuroscience
• General medicine
• Infectious disease & vaccines
• Inflammation & immunology
• Oncology

New Medicines, Novel Insights

• Advancing precision oncology
• Advancing rare disease drug development
• Accelerating development of cell and gene therapies
• Achieving patient-guided drug development

Discussions on Diversity

• Overview
• Chapter 1 Bridging the Gap
• Chapter 2 Beyond the Binary

The Regulatory Navigator

• Gene therapy: are high costs and manufacturing complexities impeding progress?
• New FDA draft guidance: Implications for simplifying interchangeability for biosimilars in the US
• Key implications for nonclinical development: FDA guidance on human gene therapy products incorporating human genome editing

INTERESTED IN PARTICIPATING?

• Healthy Volunteers
• Patient Volunteers
• Patient Advocacy Groups

HEAR FROM REAL PATIENTS

• Patient Stories

• Leadership team
• Global reach
• Our DE&I strategy
• Our ESG strategy
• Compliance, tax & privacy
• Meet us at an event